natgillin/translations-raw huggingface dataset:
Wipe the mouthpiece inside and outside to remove any powder with a clean, dry lint-free cloth.
Obrišite nastavak za usta iznutra i izvana čistom, suhom tkaninom kako biste odstranili ostatak praška.
Like other beta2-adrenergic agonists, indacaterol may produce a clinically significant cardiovascular effect in some patients as measured by increases in pulse rate, blood pressure, and/or symptoms.
Kao i ostali beta2-adrenergički agonisti, indakaterol može proizvesti klinički značajan kardiovaskularni učinak u nekih bolesnika kao što je povećanje pulsa, krvnog tlaka i/ili drugih simptoma.
Formoterol twice a day
Formoterol dva puta na dan
• if you get irregular heart beat (uncommon).
• ako imate nepravilne otkucaje srca (manje često)
The powder in the capsules is for you to inhale.
Prašak u kapsulama namijenjen je inhaliranju.
Of these patients, 2,611 were on treatment with 150 microgram once daily and 1,157 on treatment with 300 microgram once daily.
2611 od tih bolesnika bilo je liječeno dozom od 150 mikrograma jedanput na dan, a 1157 dozom od 300 mikrograma jedanput na dan.
c: indacaterol 300 microgram, formoterol and placebo MCID = minimal clinically important difference (≥1 point change in TDI, ≥4 point change in SGRQ) n/e= not evaluated at six months
MCID = najmanja klinički važna razlika (≥1 boda promjene u TDI-u, ≥4 boda promjene u SGRQ-u) n/p = nije procijenjeno u šest mjeseci
Oslif Breezhaler has no or negligible influence on the ability to drive and use machines.
Oslif Breezhaler ne utječe ili zanemarivo utječe na sposobnost upravljanja vozilima i rada sa strojevima.
What Oslif Breezhaler is and what it is used for What you need to know before you use Oslif Breezhaler How to use Oslif Breezhaler Possible side effects
Što je Oslif Breezhaler i za što se koristi Što morate znati prije nego počnete primjenjivati Oslif Breezhaler Kako primjenjivati Oslif Breezhaler Moguće nuspojave
In COPD the muscles around the airways tighten.
U KOPB-u se mišići oko dišnih puteva stežu.
Oslif Breezhaler contains the active substance indacaterol which belongs to a group of medicines called bronchodilators.
Oslif Breezhaler sadrži djelatnu tvar indakaterol koja pripada skupini lijekova koji se nazivaju bronhodilatatori.
A double-blind, placebo- and active (moxifloxacin)-controlled study for 2 weeks in 404 healthy volunteers demonstrated maximum mean (90% confidence intervals) prolongations of the QTcF interval (in milliseconds) of 2.66 (0.55, 4.77) 2.98 (1.02, 4.93) and 3.34 (0.86, 5.82) following multiple doses of 150 microgram, 300 microgram and 600 microgram, respectively.
Dvostruko slijepo, placebo i aktivno (moksifloksacinom) kontrolirano ispitivanje tijekom 2 tjedna u 404 zdrava dobrovoljca pokazalo je najveća srednja (90% intervali pouzdanosti) produljenja QTcF intervala (u milisekundama) od 2,66 (0,55, 4,77), 2,98 (1,02, 4,93) i 3,34 (0,86, 5,82) nakon višekratnih doza od 150 mikrograma, 300 mikrograma, odnosno 600 mikrograma.
After you have inhaled the medicine:
Nakon što ste udahnuli lijek:
How long to continue your treatment with Oslif Breezhaler Keep using your treatment with Oslif Breezhaler for as long as your doctor tells you.
Koliko dugo trebate nastaviti svoje liječenje Oslif Breezhalerom Nastavite svoje liječenje Oslif Breezhalerom toliko dugo koliko Vam je rekao liječnik.
If paradoxical bronchospasm occurs Oslif Breezhaler should be discontinued immediately and alternative therapy substituted.
Ako dođe do pojave paradoksalnog bronhospazma, primjenu Oslif Breezhalera treba odmah prekinuti i zamijeniti ga drugim lijekom.
• if you have difficulty breathing with wheezing or coughing (uncommon).
• ako imate otežano disanje s piskanjem pri disanju ili kašljem (manje često).
Although no clinically relevant effect on the cardiovascular system is usually seen after the administration of Oslif Breezhaler at the recommended doses, as with other beta2-adrenergic agonists, indacaterol should be used with caution in patients with cardiovascular disorders (coronary artery disease, acute myocardial infarction, cardiac arrhythmias, hypertension), in patients with convulsive disorders or thyrotoxicosis, and in patients who are unusually responsive to beta2-adrenergic agonists.
Iako nije bio zapažen klinički značajan učinak na kardiovaskularni sustav nakon primjene Oslif Breezhalera u preporučenim dozama, indakaterol treba, kao i druge beta2-adrenergičke agoniste, oprezno primjenjivati u bolesnika s kardiovaskularnim poremećajima (koronarna srčana bolest, akutni infarkt miokarda, srčane aritmije, hipertenzija), u bolesnika s konvulzivnim poremećajima ili tireotoksikozom te u bolesnika koji imaju neuobičajeni odgovor na beta2-adrenergičke agoniste.
Some people may occasionally cough briefly soon after inhaling the medicine.
Neki ljudi mogu povremeno kašljati ubrzo nakon inhaliranja lijeka.
At the recommended doses, the adverse reaction profile of Oslif Breezhaler in patients with COPD shows clinically insignificant systemic effects of beta2-adrenergic stimulation.
U preporučenim dozama profil nuspojava Oslif Breezhalera u bolesnika s KOPB-om pokazuje klinički beznačajne sistemske učinke beta2-adrenergičke stimulacije.
It is not harmful if these pieces are swallowed or inhaled.
Neće Vam naškoditi ako ih progutate ili udahnete.
Oslif Breezhaler capsules must always be stored in the blister, and only removed immediately before use.
Oslif Breezhaler kapsule se moraju uvijek čuvati u blisteru te se smiju izvaditi tek neposredno prije primjene.
Oslif Breezhaler, administered once a day at doses of 150 and 300 microgram consistently provided clinically significant improvements in lung function (as measured by the forced expiratory volume in one second, FEV1) over 24 hours across a number of clinical pharmacodynamic and efficacy studies.
Oslif Breezhaler primijenjen jedanput na dan u dozi od 150 i 300 mikrograma dosljedno je pružao klinički značajna poboljšanja plućne funkcije (mjereno forsiranim izdisajnim volumenom u jednoj sekundi, FEV1) tijekom 24 sata kroz brojna farmakodinamička ispitivanja i ispitivanja djelotvornosti.
In a human ADME study where indacaterol was given orally, the faecal route of excretion was dominant over the urinary route.
U ADME ispitivanju u ljudi, kada je indakaterol bio davan oralno, stolica je bila dominantni put izlučivanja u odnosu na mokraću.
Like other beta2-adrenergic agonists, indacaterol may inhibit labour due to a relaxant effect on uterine smooth muscle.
Kao i drugi beta2-adrenergički agonisti, indakaterol može inhibirati porod zbog učinka relaksacije na glatke mišiće maternice.
Immediate hypersensitivity reactions have been reported after administration of Oslif Breezhaler.
Reakcije preosjetljivosti su odmah bile prijavljene nakon primjene Oslif Breezhalera.
Inhaler body and cap are made from acrylonitrile butadiene styrene, push buttons are made from methyl methacrylate acrylonitrile butadiene styrene.
Tijelo inhalatora i poklopac su napravljeni od akrilonitril butadien stirena, tipke su napravljene od metil metakrilat akrilonitril butadien stirena.
• Place the mouthpiece in your mouth and close your lips firmly around it.
• Stavite nastavak u usta i usnama ga čvrsto obujmite.
Although indacaterol did not affect general reproductive performance in a rat fertility study, a decrease in the number of pregnant F1 offspring was observed in the peri- and post-developmental rat study at an exposure 14-fold higher than in humans treated with Oslif Breezhaler.
Iako indakaterol nije u pravilu utjecao na reproduktivne parametre u ispitivanju plodnosti u štakora, zapažen je pad broja trudnih F1 potomaka u ispitivanju peri- i post-razvoja u štakora pri izloženosti 14 puta većoj od one u ljudi liječenih Oslif Breezhalerom.
Indacaterol has not been shown to cause interactions with medicinal products administered concomitantly.
Pokazano je da indakaterol ne ulazi u interakcije s istodobno primijenjenim lijekovima.
Treatment comparison compared to placebo showed a ratio of rates of 0.68 (95% CI [ 0.47, 0.98]; p-value 0.036) and 0.74 (95% CI [0.56, 0.96]; pvalue 0.026) for 150 microgram and 300 microgram, respectively.
Usporedba s placebo grupom pokazala je omjer stopa od 0,68 (95% CI [ 0,47, 0,98]; p-vrijednost 0,036) i 0,74 (95% CI [0,56, 0,96]; p-vrijednost 0,026) za doze od 150 mikrograma, odnosno 300 mikrograma.
• Open the mouthpiece again, remove the empty capsule by tipping it out of the capsule chamber.
• Ponovno otvorite nastavak za usta, odstranite praznu kapsulu naginjanjem iz komore za kapsulu.
Both doses resulted in an increase of 40-50 ml over open-label tiotropium 18 microgram once a day (150 microgram, p=0.004; 300 microgram, p=0.01).
Obje su doze dovele do povećanja od 40-50 ml tijekom otvorene primjene tiotropija u dozi od 18 mikrograma jedanput na dan (150 mikrograma, p=0,004; 300 mikrograma, p=0,01).
The recommended dose is the inhalation of the content of one 150 microgram capsule once a day, using the Oslif Breezhaler inhaler.
Preporučena doza je udisanje sadržaja jedne kapsule od 150 mikrograma jedanput na dan uz pomoć Oslif Breezhaler inhalatora.
You may get all or most of the following: sore throat, runny nose, blocked nose, sneezing, coughing, headache.
Možete imati sve ili većinu od navedenog: grlobolja, curenje iz nosa,
Oslif Breezhaler, administered once a day at doses of 150 microgram and 300 microgram, showed clinically meaningful improvements in lung function.
Oslif Breezhaler primijenjen jedanput na dan u dozama od 150 mikrograma i 300 mikrograma pokazao je klinički značajna poboljšanja plućne funkcije.
Effects on the cardiovascular system attributable to the beta2-agonistic properties of indacaterol included tachycardia, arrhythmias and myocardial lesions in dogs.
U pasa, učinci na kardiovaskularni sustav vezani za beta2-agonistička svojstva indakaterola uključuju tahikardiju, aritmije i miokardijalne lezije.
Metabolism and nutrition disorders Diabetes mellitus and hyperglycaemia
Poremećaji metabolizma i prehrane Šećerna bolest i hiperglikemija
Your Oslif Breezhaler pack: Each Oslif Breezhaler pack contains: one Oslif Breezhaler inhaler one or more blister containing Oslif Breezhaler capsules to be used in the inhaler.
Vaše Oslif Breezhaler pakiranje: Jedno Oslif Breezhaler pakiranje sadrži: jedan Oslif Breezhaler inhalator jedan ili više blistera koji sadrže Oslif Breezhaler kapsule koje se koriste u inhalatoru.
Do not swallow.
Ne gutajte.
Oslif Breezhaler has not been investigated in patients with not well controlled diabetes mellitus.
Oslif Breezhaler se nije ispitivao u bolesnika s loše kontroliranom šećernom bolešću.
Indacaterol is a chiral molecule with R-configuration.
5.2 Farmakokinetička svojstva Indakaterol je kiralna molekula s R-konfiguracijom.
The inhalation of the content of one 300 microgram capsule once a day, using the Oslif Breezhaler inhaler has been shown to provide additional clinical benefit with regard to breathlessness, particularly for patients with severe COPD.
Dokazano je da udisanje sadržaja kapsule od 300 mikrograma jedanput na dan uz pomoć Oslif Breezhaler inhalatora omogućava dodatnu kliničku korist s obzirom na dispneju, osobito u bolesnika s teškim KOPB-om.
• Open the inhaler and carefully loosen the capsule by tapping the base of the inhaler.
• Otvorite inhalator i oprezno oslobodite kapsulu laganim udaranjem donjeg dijela inhalatora.
No dose adjustment is required for patients with mild and moderate hepatic impairment.
Nije potrebno prilagođavanje doze u bolesnika s blagim i umjerenim oštećenjem jetre.
Inhale the medicine: To breathe the medicine deeply into your airways:
Udahnite lijek: Kako biste udahnuli lijek duboko u dišne puteve:
Not all pack sizes or strengths may be available in your country.
Vaše zemlje ne moraju se nalaziti sve veličine pakiranja.
Indacaterol serum concentrations increased with repeated once-daily administration.
Koncentracije indakaterola u serumu rasle su s ponavljanjem primjene jedanput na dan.
If the capsule is not empty then inhale again as directed.
Ako kapsula nije prazna, tada ponovno udahnite lijek prema uputama.
Oslif Breezhaler is used to make breathing easier for adult patients who have breathing difficulties due to a lung disease called chronic obstructive pulmonary disease (COPD).
Oslif Breezhaler se koristi da bi se olakšalo disanje u odraslih bolesnika koji imaju poteškoće s disanjem zbog plućne bolesti koja se zove kronična opstruktivna plućna bolest (KOPB).
INTERMEDIATE CARTON OF MULTIPACK (WITHOUT BLUE BOX)
SREDNJA KUTIJA VIŠESTRUKOG PAKIRANJA (ISKLJUČUJUĆI PLAVI OKVIR)
medicines called beta blockers that are used for high blood pressure or other heart problems (such as propranolol), or for the eye problem called glaucoma (such as timolol).
Veća je vjerojatnost za nuspojave. lijekove zvane beta blokatori koji se koriste za visoki krvni tlak ili druge srčane probleme (kao što je propranolol), ili za problem s očima koji se zove glaukom (kao što je timolol). lijekove koji snižavaju količinu kalija u Vašoj krvi.
Some people occasionally cough soon after inhaling the medicine.
Neki ljudi povremeno kašlju ubrzo nakon udisanja lijeka.
Both doses demonstrated statistically significant improvements in symptom relief over placebo for dyspnoea and health status (as evaluated by Transitional Dyspnoea Index [TDI] and St. George's Respiratory Questionnaire [SGRQ], respectively).
Obje doze su pokazale statistički značajna poboljšanja s obzirom na smanjenje simptoma dispneje i zdravstvenog stanja u usporedbi s placebom (procijenjeno pomoću Prijelaznog indeksa dispnejeengl.
Do not take the inhaler apart.
Nemojte rastavljati inhalator.
Beta2-adrenergic agonists may produce significant hypokalaemia in some patients, which has the potential to produce adverse cardiovascular effects.
Beta2-adrenergički agonisti mogu uzrokovati znatnu hipokalijemiju u nekih bolesnika što može uzrokovati kardiovaskularne nuspojave.
• if you get crushing chest pain, (common).
• ako imate razarajuću bol u prsima, (često).
Breathe out:
Izdahnite:
Oslif Breezhaler is not indicated for the treatment of acute episodes of bronchospasm, i.e. as rescue therapy.
Oslif Breezhaler nije indiciran za liječenje akutnih epizoda bronhospazma, tj. kao lijek za hitna stanja.
What you need to know before you use Oslif Breezhaler
Što morate znati prije nego počnete primjenjivati Oslif Breezhaler
Oslif Breezhaler contains lactose
Oslif Breezhaler sadrži laktozu
Pooled efficacy analysis over 6 months' treatment demonstrated that the rate of COPD exacerbations was statistically significantly lower than the placebo rate.
Objedinjena analiza djelotvornosti tijekom 6 mjeseci liječenja pokazala je značajno nižu stopu egzacerbacija KOPB-a nego u placebo grupi.
The capsules must only be removed from the blister immediately before use.
Kapsule se smiju izvaditi iz blistera tek neposredno prije primjene.
If you forget to inhale a dose, inhale just one dose at the usual time the next day.
Ako ste zaboravili primijeniti Oslif Breezhaler Ako ste zaboravili udahnuti svoju dozu, udahnite samo jednu dozu u uobičajeno vrijeme sljedećeg dana.
What Oslif Breezhaler contains - Each Oslif Breezhaler 150 microgram capsule contains 150 microgram indacaterol as indacaterol maleate.
Što Oslif Breezhaler sadrži - Svaka Oslif Breezhaler 150 mikrogramska kapsula sadrži 150 mikrograma indakaterola u obliku indakaterolmaleata.
The Oslif Breezhaler Phase III clinical development programme involved patients with a clinical diagnosis of moderate to severe COPD.
Program ispitivanja faze III tijekom razvoja Oslif Breezhalera uključivao je bolesnike s kliničkom dijagnozom umjerenog do teškog KOPB-a.
Only use the capsules with the inhaler provided in this pack (Oslif Breezhaler inhaler).
Koristite samo kapsule koje ste dobili uz inhalator u ovom pakiranju (Oslif Breezhaler inhalator).
If you do, don't worry.
Nemojte biti zabrinuti ako kašljete.
Tiotropium once a day
Tiotropij jedanput na dan
Release the side buttons fully.
Potpuno otpustite bočne tipke.
Hold the base of the inhaler firmly and tilt the mouthpiece.
Čvrsto držite donji dio inhalatora i otklopite nastavak za usta.
The mean accumulation ratio of indacaterol, i.e. AUC over the 24-h dosing interval on Day 14 compared to Day 1, was in the range of 2.9 to 3.5 for once-daily inhaled doses between 150 microgram and 600 microgram.
AUC tijekom 24-satnog razdoblja doziranja 14. dana u usporedbi s 1. danom bio je u rasponu od 2,9 do 3,5 za doze od 150 mikrograma do 600 mikrograma inhalirane jedanput na dan.
There are no data available for use of Oslif Breezhaler in patients with severe hepatic impairment.
Nema podataka o primjeni Oslif Breezhalera u bolesnika s teškim oštećenjem jetre.
Mean peak improvements in FEV1 relative to baseline were 250-330 ml at steady state.
U stanju dinamičke ravnoteže srednja vršna poboljšanja FEV1-a u odnosu na početne vrijednosti bila su 250-330 ml.
Each capsule contains 24.6 mg lactose.
Pomoćna tvar s poznatim učinkom Svaka kapsula sadrži 24,6 mg laktoze.
In the event of deterioration of COPD during treatment with Oslif Breezhaler, a re-evaluation of the patient and of the COPD treatment regimen should be undertaken.
Ako dođe do pogoršanja KOPB-a tijekom liječenja Oslif Breezhalerom, bolesnika treba ponovno pregledati i provesti liječenje KOPB-a.
Lung function
Plućna funkcija
Do not wash your inhaler with water.
Nemojte prati inhalator vodom.
What Oslif Breezhaler is and what it is used for
Što je Oslif Breezhaler i za što se koristi
The 300 microgram dose resulted in a 170-180 ml increase compared to placebo (p<0.001) and a 100 ml increase compared to formoterol 12 microgram twice a day (p<0.001).
Doza od 300 mikrograma dovela je do povećanja od 170-180 ml u usporedbi s placebom (p<0,001) te do povećanja od 100 ml u usporedbi s formoterolom u dozi od 12 mikrograma dva puta na dan (p<0,001).
• if you get symptoms of an allergic reaction such as rash, itching, hives, difficulty breathing or swallowing, dizziness (uncommon).
• ako imate simptome alergije poput osipa, svrbeži, urtikarije, poteškoće u disanju ili gutanju,
Each capsule contains 24.8 mg lactose.
Pomoćna tvar s poznatim učinkom Svaka kapsula sadrži 24,8 mg laktoze.
Oslif Breezhaler is a single-dose inhalation device.
Oslif Breezhaler je jednodozni inhalator.
Oslif Breezhaler 150 microgram capsules have a black product code “IDL 150” printed above a black bar and a black company logo ( ) printed below the black bar.
Oslif Breezhaler 150 mikrograma kapsule imaju crnu oznaku „IDL 150“ otisnutu iznad crne crte i crni logo proizvođača ( ) otisnut ispod crne crte.
Upon initiation of treatment with Oslif Breezhaler plasma glucose should be monitored more closely in diabetic patients.
Nakon početka liječenja Oslif Breezhalerom, u bolesnika sa šećernom bolešću treba pomno pratiti glukozu u plazmi.
The Oslif Breezhaler inhaler provided with each new prescription should be used.
Potrebno je koristiti Oslif Breezhaler inhalator koji se dobije sa svakim novim receptom.
Percentage of days with no rescue medication use a
Postotak dana bez primjene lijeka za hitno ublažavanje simptoma
Tell your doctor immediately if your COPD symptoms (breathlessness, wheezing, cough) do not improve or get worse.
To mogu biti znaci stanja koje se naziva bronhospazam. odmah se obratite svom liječniku ako Vam se simptomi KOPB-a (nedostatak daha prilikom udisanja, piskanje pri disanju, kašalj) nisu popravili ili ako su se pogoršali.
Other medicines and Oslif Breezhaler
Drugi lijekovi i Oslif Breezhaler
At the 12-week primary endpoint (24-hour trough FEV1), the 150 microgram dose resulted in a 130-180 ml increase compared to placebo (p<0.001) and a 60 ml increase compared to salmeterol 50 microgram twice a day (p<0.001).
Kao primarni ishod nakon 12 tjedana (24satni najniži FEV1), doza od 150 mikrograma dovela je do povećanja od 130-180 ml u usporedbi s placebom (p<0,001) te povećanje od 60 ml u usporedbi sa salmeterolom u dozi od 50 mikrograma dva puta na dan (p<0,001).
300 microgram, tiotropium and placebo;
300 mikrograma, formoterolom i placebom
Each inhaler should be disposed of after 30 days of use.
Svaki nhalator treba baciti nakon 30 dana uporabe.
Mark daily dose tracker:
Označite uzimanje dnevne doze na kalendariću:
Oslif Breezhaler 300 microgram capsules have a blue product code “IDL 300” printed above a blue bar and a blue company logo ( ) printed below the blue bar.
Oslif Breezhaler 300 mikrograma kapsule imaju plavu oznaku „IDL 300“ otisnutu iznad plave crte i plavi logo proizvođača ( ) otisnut ispod plave crte.
The Oslif Breezhaler inhaler enables you to inhale the medicine contained in a capsule.
Oslif Breezhaler inhalator Vam omogućava udisati lijek koji se nalazi u kapsuli.
Stop using the medicine and tell your doctor immediately if you get tightness of the chest, coughing, wheezing or breathlessness immediately after using the medicine.
Tijekom liječenja Oslif Breezhalerom, prestanite primjenjivati lijeka i odmah se obratite svom liječniku ako osjetite stezanje grudnog koša, kašljanje, piskanje ili kratkoću daha odmah nakon primjene lijeka.
Always keep the Oslif Breezhaler inhaler and capsules in a dry place.
Uvijek držite Oslif Breezhaler inhalator i kapsule na suhom mjestu.
1.0 b a n/e a
1,2 a n/p
Show the pack of Oslif Breezhaler.
Pokažite pakiranje Oslif Breezhalera.
Do not use Oslif Breezhaler capsules with any other inhaler, and do not use Oslif Breezhaler inhaler to take any other capsule medicine.
Oslif Breezhaler kapsule s nekim drugim inhalatorom i ne koristite Oslif Breezhaler inhalator za primjenu bilo kojeg drugog lijeka u kapsulama.
These were in the vast majority mild or moderate and became less frequent if treatment was continued.
One su najčešće bile blage do umjerene, a nastavkom liječenja bi se prorijedile.
Pull off the cap.
Skinite poklopac.
Inhalation powder, hard capsules
Prašak inhalata, tvrde kapsule
Driving and using machines It is unlikely that Oslif Breezhaler will affect your ability to drive and use machines.
Nije vjerojatno da će Oslif Breezhaler utjecati na Vašu sposobnost upravljanja vozilima ili strojevima.
The delivered dose leaving the mouthpiece of the inhaler is indacaterol maleate equivalent to 240 microgram indacaterol.
Doza indakaterolmaleata koja izlazi iz nastavka za usta inhalatora odgovara 240 mikrograma indakaterola.
Oslif Breezhaler capsules must not be swallowed.
Oslif Breezhaler kapsule se ne smiju progutati.
The magnitude of response was generally greater than seen with active comparators (Table 2).
U odnosu na druge aktivne komparativne lijekove, stupanj odgovora bio je općenito veći (Tablica 2).
Oslif Breezhaler is indicated for maintenance bronchodilator treatment of airflow obstruction in adult patients with chronic obstructive pulmonary disease (COPD).
Oslif Breezhaler je indiciran za terapiju održavanja bronhodilatacije kod opstrukcije dišnih puteva u odraslih bolesnika s kroničnom opstruktivnom plućnom bolesti (KOPB).
Renal impairment No dose adjustment is required for patients with renal impairment.
Nije potrebno prilagođavanje doze u bolesnika s oštećenjem bubrega.
Oslif Breezhaler inhaler
Oslif Breezhaler inhalator
• Close the inhaler and replace the cap.
• Zatvorite inhalator i vratite poklopac natrag.
The delivered dose leaving the mouthpiece of the inhaler is indacaterol maleate equivalent to 120 microgram indacaterol.
Doza indakaterolmaleata koja izlazi iz nastavka za usta inhalatora odgovara 120 mikrograma indakaterola.
Carton containing 30 capsules and one Oslif Breezhaler inhaler.
Kutija sadrži 30 kapsula i jedan Oslif Breezhaler inhalator.
• Do not swallow the capsules.
• Ne gutajte kapsule.
The Oslif Breezhaler inhaler enables you to inhale the medicine contained in an Oslif Breezhaler capsule.
Oslif Breezhaler inhalator Vam omogućuje udisanje lijeka koji se nalazi u Oslif Breezhaler kapsuli.
- Each Oslif Breezhaler 300 microgram capsule contains 300 microgram indacaterol as indacaterol maleate.
- Svaka Oslif Breezhaler 300 mikrogramska kapsula sadrži 300 mikrograma indakaterola u obliku indakaterolmaleata.
When you start a new pack, use the new Oslif Breezhaler inhaler that is supplied in the pack.
Kada otvorite novo pakiranje, upotrijebite novi Oslif Breezhaler inhalator koji je priložen u pakiranju.